Skip to main content

Diabetes Mellitus: Pharmacotherapy-TZDs!

 PHARMACOTHERAPY: THIAZOLIDINEDIONES

  • Commonly referred to as TZDs or Glitazones,Thiazolidinediones have established a role in T2DM Therapy.

Mechanism of Action:

  • TZDs are known to increase insulin sensitivity by stimulating peroxisome proliferator-activated receptor gamma (PPAR-g). Stimulation of PPAR-g results in a number of intracellular and extracellular changes including increased insulin sensitivity and decreased plasma fatty acid levels.

Pharmacokinetics:

  • The onset of TZDs is delayed for several weeks and require up ton 12 weeks before maximum effects are observed.

Therapy:

  • As monotherapy, TZDs reduce FPG levels by around 60-70mg/dL and the effect of A1c is up to 1.5% reduction.


Clinical Uses:

  • Pioglitazone and Rosiglitazone increases HDL. Pioglitazone increases HDL by 5.2mg/dL Rosiglitazone increases HDL levels by 2-4mg/dL.
  • Pioglitazone decreases serum Triglycerides by an average of 51.9mg/dL. Rosiglitazone increases serum triglycerides.
  • Pioglitazone increases LDL levels by 12.3 mg/dL. Rosiglitazone increases LDL levels by 21.3mg/dL.


Adverse Effects:

  1. Fluid retention
  2. Edema
  3. Hepatotoxicity
  4. It is known that blood volume increases approximately 10% with these agents resulting in approximately 4-5% patients developing edema.


Contraindications:

These drugs are contraindicated in pt. with;

  • in situations in which increased fluid retention is detrimental such as heart failure.
  • Insulin therapy
  • Patients with a baseline alanine aminotransferase (ALT) level greater than 2.5 times the upper limit of normal.
  • Increased rate of upper and lower limb fractures tends to occur with TZD therapy, hence patients with baseline fracture risk are contraindicated to receive TZDs.
  • Premenopausal women may begin to ovulate on TZD therapy and therefore counselling should be provided to all women capable to begin pregnant regarding this.
  • TZD is pregnancy category C drug, so proper precautions to avoid pregnancy should be used.
  •   In June 2011, the FDA alerted healthcare providers and patients that pioglitazone was found to be associated with an increased risk of bladder cancer after 1 year of therapy in ongoing epidemiological study.
  • As 2007 meta-analysis conducted by Nissen and colleagues, reported that non-significant increase in myocardial infarction with Rosiglitazone compared with other oral agents.
  • A subsequent prospective study found Rosiglitazone use to be associated with a non-significant increase in Myocardial infarction risk and non-significant reduction in stroke, but a trend towards increased cardiovascular risk in those patients with Ischemic stroke.
  • In May 2011, the FDA chose to restrict access and distribution of Rosiglitazone. It is currently only available through the Avandia-Rosiglitazone Medicines access Program for patients currently benefiting from the drug and in those who cannot achieve adequate disease management with other agents or who are not willing to use pioglitazone-containing medications after counselling with their healthcare provider.



Labels:

Comments

Post a Comment

Popular posts from this blog

General Mechanism of Actions of INSULIN.

GENERAL MECHANISM OF ACTION OF INSULIN AND RELATE HORMONES The body's main fuel is Glucose. Glucose is stored in the liver and muscles as Glycogen.  Excess glucose is stored in the adipose tissues which yield fatty acids via lipolysis. In the fasting state, free fatty acids supply much of the energy needs of the body except for the CNS which requires Glucose to function normally. Proteins can also be converted to glucose via gluconeogenesis. RELEASE OF INSULIN AND GLUCAGON Insulin and Glucagon are produced in the pancreas by the Islets of Langerhans . Beta cells   make up 70%-90% of the Islets and produce Insulin and Amylin while the a-cells   produce glucagon. The main function of insulin is to decrease blood glucose levels. Glucagon, along with other counter-regulatory hormones such as growth factor, cortisol, and Epinephrine, increases Blood glucose levels.  The opposing actions of Glucagon and Insulin along with other counter-regulatory hormones maintain a norma...
Post a Comment
Read more

Diabetes Mellitus: Its Goals Of Therapy!

  GOAL OF THERPY The goals of treatment of DM includes; Reducing, controlling and managing long-term microvascular, macrovascular and neuropaathic complications. Preserving beta cell function. Preventing acute complications from increased Blood glucosel level. Minimizing hypoglycemic episodes. Maintaining patient quality of life. --Two landmark trials, THE DIABETES CONTROL AND COMPLICATION TRIAL (DCCT) and THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY(UKPDS), showed that lowering blood glucose levels decreased the risk of developing chronic complications. --A near normal blood glucose level can be achieved with appropriate patient education , lifestyle modification and medications . --Proper care of DM requires goal setting and assessment for glycemic control , self-monitoring of blood glucose (SMBG) monitoring of blood glucose pressure , and lipid levels , regular monitoring for the development of complications , dietary and exercise lifestyle modifications and proper medicatio...
Post a Comment
Read more

Diabetes Mellitus: Clinical Presentation and Diagnosis!

 CLINICAL PRESENTATION AND DIAGNOSIS OF DM 2. SCREENING American Diabetes Association (ADA) recommends routine screening for T2 DM every 3 years in all adults starting at 45 years of age. Testing of T2 DM should be considered in any adult, regardless of their age, who have a BMI greater than or equal to 25kg/m2. The ADA does not currently recommend widespread screening for T1 DM because of the relatively low incidence in the general population, although measurement of Islet antibodies may be appropriate for high-risk individuals. 3.GESTATIONAL DIABETES: "Gestational diabetes is the glucose intolerance in women during pregnancy". All pregnant women who have risk factors for T2 DM should be screened for undiagnosed T2 DM at their first prenatal visit using standard diagnostic criteria.  Any women found to have diabetes in the early point at pregnancy is considered to have T2 DM or GDM. All other pregnant women, not currently known to have DM should be screened for GDM with a 75...
Post a Comment
Read more